Inherited Risk Evaluation Tool (InheRET): Identifying Patients at Increased Risk for Hereditary Disease
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- David Keren, MD
InheRET, Inc
Principal Investigator - Elena Stoffel, MD
University of Michigan
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Inheret, Inc.
Ann Arbor, Michigan, United States
- Michigan Medicine
Ann Arbor, Michigan, United States
- Hamilton Community Health Network - Withdrew From Study
Flint, Michigan, United States
- Ascension St. Mary'S Hospital - Withdrew From Study
Saginaw, Michigan, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 1 Sept 2020
- Primary completion
- 30 Jun 2022
- Completion
- 31 Aug 2022
- Last update posted
- 30 Jul 2021
- Registered enrollment
- 2,232
- Registry id
- NCT04510896
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 30 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.